Daily notes / October 15, 2026

Third Point filed a Schedule 13D reporting a 5.8% stake in Strata Critical Medical

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of October 15, 2026. Published October 17, 2026. 2 min read.

Tall office buildings around Trinity Church in lower Manhattan seen from above, with the church spire between the towers. — Skyscrapers around Trinity Church, New York, 1905. Photo: Detroit Publishing Company (scan by the New York Public Library), Public domain (scan of a 1905 photograph, New York Public Library Digital Collections). Original

The short answer

Third Point LLC filed a Schedule 13D on Oct 15, 2026, reporting 5,126,511 shares, or 5.8% of the class of Strata Critical Medical (SRTA). The filing records ownership, not when shares were bought. Other public records include fund 13F filings, short-interest data and share-price moves around the filing date.

What did Third Point file?

Third Point LLC filed a Schedule 13D on Oct 15, 2026. The filing reports 5,126,511 shares, 5.8% of the class of Strata Critical Medical (SRTA).

A Schedule 13D is an ownership filing, not a trade record. The filing does not say when the reported shares were bought.

When was the filing made?

The filing was made 70 days after the company's results announcement of Aug 4, 2026, identified as an 8-K Item 2.02. That timing places the filing after the results announcement, but does not establish when the shares were acquired.

What do other fund filings show?

Fund 13F filings recorded in the 90 days to Oct 15, 2026 show 0 new or larger positions and 1 smaller or closed position in Strata Critical Medical.

For the quarter ended Jun 30, 2026, Royce & Associates LP was the largest position that grew, increasing 316,561 shares. ARK Investment Management was the largest position that shrank, reducing 4,724,429 shares; Amova Asset Management Americas, Inc. reduced 665,261 shares.

A 13F is a quarter-end snapshot with no trade date. It does not provide the timing of transactions within the quarter.

What market data and coverage were recorded around the filing?

FINRA short interest for SRTA on the settlement date of Sep 30, 2026 was 4,331,692 shares, −0.62% on the previous report, or about 6.07 days of average volume.

SRTA closed at $4.45 on Oct 13, 2026, the last session on or before the filing date. From Sep 14, 2026 to Oct 13, 2026, the close moved from $5.36 to $4.45, a change of −17.0%. These share-price moves are context only and do not explain the filing.

Finnhub listed Benzinga coverage with the headline “Third Point's Daniel Loeb Urges Strata Critical Medical To Explore Strategic Alternatives Including Potential Sale” on Oct 15, 2026. Finnhub also listed another Benzinga headline, “Strata Critical Medical 13D Filing Shows Third Point Reports 5.8% Stake In Co. As Of Oct. 13,” on Oct 15, 2026. These are headlines as listed by the outlet; OQRO has not checked them and does not summarise the articles.

What this does not tell you?

The Schedule 13D reports ownership, not a transaction date, and does not say when shares were bought. The 13F records are quarter-end snapshots without trade dates. The filing does not explain share-price moves, and other news can move a price.

This article describes public filings and records. It is not investment advice. See Strata Critical Medical on OQRO.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data